COVID-19: 3D Bioprinted Tissue Models for Respiratory Viruses
Document text
Principal Investigator: Marc Ferrer-Alegre Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES Fiscal Year: 2020 Award: $711,776 Funding agency: National Center for Advancing Translational Sciences We have made significant progress on several of our goals and objectives listed above over the past few months. Accomplishments are written according to objective number. 1. We have established optimized protocols for culturing primary human small airway epithelial cells and alveolar cells in a transwell air-liquid-interface (ALI) model. We are miniaturizing to 96-well plate formats and optimizing the addition of vasculature units. We have also gained extensive experience working with MatTek's tracheobronchial and alveolar cultures. 2. We have established infection of human 3D lung tissue (tracheobronchial, alveolar, and small airway) with influenza virus and optimized detection conditions. We have also established infection of 3D ALI tracheobronchial tissues with SARS-CoV2, and are able to directly and robustly detect SARS-CoV2 antigen in tissue. 3. We have confirmed robust antiviral activity of remdesivir and interferon type I in 3D ALI tracheobronchial tissues infected with SARS-CoV2. We are using this model to analyze the antiviral activity of select compounds identified from high throughput screening that was carried out in collaboration with Sara Cherry at the University of Pennsylvania. We are continuing to study the reproducibility of infection in these tissues for screening purposes. 4. scRNAseq studies are currently ongoing. Terms: <2019 novel coronavirus><2019-nCoV><3-D><3-Dimensional><3D><Address><Air><Alveolar><Alveolar Cell><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biologic Assays><Biological Assay><Body Tissues><Brain><Brain Nervous System><COVID><COVID-19><COVID19><Cardiac><Cell Body><Cells><Cherries><Cherry - dietary><Clinical><CoV disease><Collaborations><Communities><Coronaviridae><Coronavirus><Detection><Disease><Disorder><Drugs><Encephalon><Epithelial Cells><Funding><GS-5734><Goals><High Throughput Assay><Human><Immune><Immunes><In Vitro><Infection><Influenza Virus><Interferon Type I><Intestinal><Intestines><Kidney><Kidney Urinary System><Laboratories><Liquid substance><Lung Parenchyma><Lung Tissue><Medication><Modeling><Modern Man><NIAID><National Institute of Allergy and Infectious Disease><Pathology><Pennsylvania><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiologic><Physiological><Position><Positioning Attribute><Protocol><Protocols documentation><Public Health><Reproducibility><Research Activity><Research Support><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Societies><Structure of parenchyma of lung><System><Testing><Therapeutic Intervention><Tissue Model><Tissues><Tracheobronchial><Translational Research><Translational Science><Universities><Vaccines><Viral Diseases><Viral Respiratory Tract Infection><Virus><Virus Diseases><Wuhan coronavirus><airway epithelium><anti-viral agents><anti-viral drugs><anti-virals><atypical pneumonia><bio-fabrication><bio-printing><biofabrication><bioprinting><bowel><clinical efficacy><corona virus><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><drug/agent><experience><fluid><high throughput screening><immunogen><in vitro Assay><in vivo><influenzavirus><intervention therapy><liquid><miniaturize><novel><pandemic><pandemic disease><parainfluenza virus><pathogen><remdesivir><renal><respiratory><respiratory virus><response><screening><therapeutic agent development><therapeutic development><three dimensional><translation research><viral infection><viral respiratory infection><virus infection><virus-induced disease>